The CD40/CD40 ligand system: linking inflammation with atherothrombosis.

Content Provider	Semantic Scholar
Author	Antoniades, Charalambos Bakogiannis, Constantinos Tousoulis, Dimitris Antonopoulos, Alexios S. Stefanadis, Christodoulos
Copyright Year	2009
Abstract	The role of CD40/CD40 ligand (CD40L) in atherothrombosis is now widely accepted. However, the exact mechanisms linking the CD40/CD40L system and the soluble form of CD40 ligand (sCD40L) with atherothrombosis are currently a topic of intensive research. CD40L and sCD40L belong to the tumor necrosis factor superfamily, and they are molecules with a dual prothrombotic and proinflammatory role. They are expressed in a variety of tissues such as the immune system (in both B and T cells), the vascular wall, and activated platelets. Soluble CD40L has multiple autocrine, paracrine, and endocrine actions, and it may trigger key mechanisms participating in atherothrombosis. CD40/CD40L may participate in the development of coronary atherosclerosis and the triggering of acute coronary syndromes, while sCD40L seems to have a prognostic role not only in subjects with advanced atherosclerosis but also in the general population. Although conventional cardiovascular medication such as antiplatelet therapy, statins, angiotensin-converting enzyme inhibitors, and many others have been shown to reduce both sCD40L and cardiovascular risk, it is still unclear whether specific treatments targeting the CD40/CD40L system will prove to be beneficial against atherothrombosis in the near future.
File Format	PDF HTM / HTML
DOI	10.1016/j.jacc.2009.03.076
PubMed reference number	19679244
Journal	Medline
Volume Number	54
Issue Number	8
Alternate Webpage(s)	http://www.onlinejacc.org/content/accj/54/8/669.full.pdf
Alternate Webpage(s)	https://doi.org/10.1016/j.jacc.2009.03.076
Journal	Journal of the American College of Cardiology
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article